What Recent Performance Says About Omnicell Stock

Omnicell (OMCL) has drawn investor attention after a period of weaker share performance, with the stock down about 22% over the past month and roughly 24% over the past 3 months.

This recent decline contrasts with a market value of about US$1.53b and annual revenue of US$1.25b. These figures give investors a concrete starting point to size up the business against its current share price.

Omnicell’s recent slide fits into a wider losing streak, with the 7 day share price return down 5.9% and the year to date share price return down 26%, while the 1 year total shareholder return is roughly flat and longer term total returns remain deeply negative.

Spot 46 high quality undervalued stocks that, like Omnicell after its recent share price slide, combine solid business scale with market prices that may not fully reflect their underlying fundamentals.

Bulls see Omnicell’s recent US$1.25b revenue base and net income as underappreciated after the share price slide. Bears focus on the long term track record of weak returns. Which side do the current valuation numbers support?

Most Popular Narrative: 45.5% Undervalued

The most followed narrative sets Omnicell’s fair value at $61.29 compared with the last close at $33.41, which implies a wide gap the market is currently pricing in.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Want to see what drives that valuation gap on Omnicell? The narrative focuses on recurring revenue, higher margins, and a richer earnings multiple. Curious which specific growth and profit assumptions sit underneath those cash flow projections and discount rate inputs? The full narrative spells out the numbers behind that fair value assessment.

Result: Fair Value of $61.29 (UNDERVALUED)

However, Omnicell’s story could shift quickly if tariff costs squeeze margins more than expected or if macro pressure slows hospital spending on new automation projects.

Another View on Omnicell’s Valuation Using Earnings Multiples

Analysts and the SWS fair value model see Omnicell as trading about 45.4% below an estimated intrinsic value, yet the current P/E of roughly 39x looks demanding next to a fair ratio of 27.6x and peer and industry averages of 28.9x and 26.6x. That gap suggests investors are paying up for the earnings stream even after the share price slide. Which signal do you trust more when you weigh risk against potential reward?

Next Steps

The mixed tone of this Omnicell story makes it important to check the data for yourself and act before sentiment shifts again. To see why some investors are optimistic, review the detailed breakdown of its 4 key rewards.

Looking for more Omnicell style investment ideas?

If Omnicell has your attention, do not stop here. The real edge often comes from comparing a few strong alternatives side by side before making any move.

• Target reliable compounding potential by reviewing companies that score well on resilience through the 76 resilient stocks with low risk scores.
• Hunt for quality on sale by scanning the 46 high quality undervalued stocks that pair solid fundamentals with prices that may not reflect their strengths.
• Strengthen your shortlist with a list of solid balance sheet and fundamentals (50 results) so you are not caught off guard by fragile financial positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.